Welcome to Seeking Alpha's Wall Street breakfast, where we cover the top news for investors

every morning and afternoon.

Good morning and happy Friday. Today is January 19th and I'm your host for today

Rina Sherbal Julie Morgan is back next week. No shutdown. Congress clear

stop-gap spending bill, diabetes drugs see price raises, and NASDAQ 100 rides tech

optimism to all-time high. U.S. Congress cleared a temporary spending bill to fund the

government into early March

averting a partial shutdown ahead of an expected snowstorm and buying more time

for lawmakers to hammer out funding bills for the fiscal year that started in October.

The Senate voted for the continuing resolution 77 to 18,

while the House voted 314 to 108.

The temporary bill will fund certain government operations until March 1st,

while the deadline for the remaining has been pushed to March 8th.

Funding would have run out on January 19th today and February 2nd under current law. This is the third extension made

for fiscal 2024 since October 1st. The White House press secretary said

Biden would sign the resolution.

Two popular diabetes medicines from Eli Lilly and Novo Nordisk,

Monjaro and Ozembeck saw a list price hikes in the first half of January.

According to analysis performed for the Wall Street Journal,

Monjaro's price rose 4.5% to 1,070 for a one month supply. Ozempix price rose

by 3.5% to about $970 for one month.

The Wall Street Journal noted that prices were hiked on hundreds of other drugs this month

...